ICD-10 Coding for Colony-Stimulating Factor(D70.1, D70.1A, D70.1B)
Comprehensive guide on ICD-10 coding for colony-stimulating factors, including documentation requirements, common pitfalls, and billing considerations.
Complete code families applicable to Colony-Stimulating Factor
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| D70.1 | Agranulocytosis secondary to cancer chemotherapy | Use when neutropenia is a result of chemotherapy treatment. |
|
| J2505 | Injection, pegfilgrastim, 6 mg | Use for prophylactic administration post-chemotherapy. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutColony-Stimulating Factor
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Colony-Stimulating Factor.
Omitting ANC values in documentation
Impact
Clinical: Inadequate justification for CSF use., Regulatory: Non-compliance with documentation standards., Financial: Potential for claim denials.
Mitigation
Include ANC values in all CSF-related documentation, Use standardized templates
Incorrect sequencing of CSF codes
Impact
Reimbursement: May result in claim denials or reduced payment., Compliance: Non-compliance with ICD-10 guidelines., Data Quality: Inaccurate clinical data representation.
Mitigation
Always sequence underlying malignancy first, followed by neutropenia and CSF administration codes.
CSF administration documentation
Impact
Inadequate documentation of CSF use can lead to audit findings.
Mitigation
Use detailed templates and ensure all required elements are documented.